Regentis Biomaterials (RGNT) Total Non-Current Liabilities (2024)
Regentis Biomaterials (RGNT) posted quarterly Total Non-Current Liabilities of $6.3 million for Q4 2024.
Regentis Biomaterials (RGNT) Total Non-Current Liabilities (2024) Analysis & Trends
Regentis Biomaterials (RGNT) has reported Total Non-Current Liabilities for 1 consecutive years, with $6.3 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Total Non-Current Liabilities changed N/A year-over-year to $6.3 million; the TTM figure through Dec 2024 stood at $6.3 million (changed N/A YoY), while the FY2024 annual figure was $6.3 million, up 1115.73% from the prior year.
- Total Non-Current Liabilities was little changed at $6.3 million in Q4 2024 per RGNT's latest filing.
- Across five years, Total Non-Current Liabilities topped out at $6.3 million in Q4 2024 and bottomed at $6.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.25 Bn | 129.03 Bn | 1.96 Bn | 1.92 Bn |
| 2 | Becton Dickinson | 52.47 Bn | 51.61 Bn | 2.32 Bn | 48.34 Bn |
| 3 | Alcon | 35.69 Bn | 34.34 Bn | 1.68 Bn | 6.34 Bn |
| 4 | Resmed | 33.67 Bn | 32.20 Bn | 861.22 Mn | 985.45 Mn |
| 5 | Medline | 29.17 Bn | 26.49 Bn | 2.22 Bn | 17.56 Bn |
| 6 | West Pharmaceutical Services | 25.06 Bn | 24.62 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Solventum | 15.36 Bn | 14.95 Bn | 1.29 Bn | 8.96 Bn |
| 8 | Cooper Companies | 14.79 Bn | 14.65 Bn | 735.40 Mn | 3.98 Bn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 12.41 Bn |
| 10 | Regentis Biomaterials | 1.20 Mn | -6.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6.33 Mn |